title: Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.
abstract: Cancer cells are often dependent on epigenetic pathways for their survival. Consequently, drugs that target the epigenome, rather than the underlying DNA sequence, are currently attracting considerable attention. In recent years, the first epigenetic drugs have been approved for cancer chemotherapy, mainly for hematological applications. Limitations in single-drug efficacies have thus far limited their application in the treatment of solid tumors. Nevertheless, promising activity for these compounds has been suggested when combined with other, distinctly targeted agents. In this review, we discuss the anti-angiogenic activity of histone deacetylase and DNA methyltransferase inhibitors and their combinations with other targeted (anti-angiogenic) therapeutics in treatment of solid tumors. The role that these inhibitors play in the inhibition of tumor angiogenesis, particularly in combination with other targeted agents, and the advantages they present over broad acting anticancer agents, are critically discussed.
authors.affiliation: Department of Medical Oncology, VU University Medical Center, 1007, MB, Amsterdam, The Netherlands.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Berndsen
authors.affiliation: Department of Medical Oncology, VU University Medical Center, 1007, MB, Amsterdam, The Netherlands.
authors.forename: U Kulsoom
authors.initials: UK
authors.lastname: Abdul
authors.affiliation: School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211, Geneva, Switzerland.
authors.forename: Andrea
authors.initials: A
authors.lastname: Weiss
authors.affiliation: School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211, Geneva, Switzerland.
authors.forename: Marloes
authors.initials: M
authors.lastname: Zoetemelk
authors.affiliation: Department of Medical Oncology, VU University Medical Center, 1007, MB, Amsterdam, The Netherlands.
authors.forename: Marije T
authors.initials: MT
authors.lastname: Te Winkel
authors.affiliation: Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology, 1015, Lausanne, Switzerland.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Dyson
authors.affiliation: Department of Medical Oncology, VU University Medical Center, 1007, MB, Amsterdam, The Netherlands.
authors.forename: Arjan W
authors.initials: AW
authors.lastname: Griffioen
authors.affiliation: School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211, Geneva, Switzerland. Patrycja.Nowak-Sliwinska@unige.ch.
authors.forename: Patrycja
authors.initials: P
authors.lastname: Nowak-Sliwinska
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044127:Epigenesis, Genetic / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors
keywords: Anti-angiogenesis; Clinical trials; Combination therapy; DNA methyltransferase inhibitors; Epi-drugs; Histone deacetylase inhibitors; Solid tumors; Tumor vasculature